New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
13:02 EDTARWR, RHHBY, BMY, MRK, NVSAnalyst: Arrowhead Research could be in early stages of major run, Barron's says
RBC analyst Michael Yee believes Arrowhead Research is in the early innings of a potentially major run, according to Barron's. Yee cites the company's promising lead drug for Hep B, its RNAi platform technology, and the fact that it could partner with larger firms such as Roche (RHHBY), Bristol Myers (BMY), Merck (MRK), and Novartis (NVS).Reference Link
News For ARWR;RHHBY;BMY;MRK;NVS From The Last 14 Days
Check below for free stories on ARWR;RHHBY;BMY;MRK;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 13, 2014
10:33 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
10:20 EDTARWRHigh option volume stocks
Subscribe for More Information
09:15 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:56 EDTARWRArrowhead should trade up on Hep B data, says RBC Capital
RBC Capital said Arrowhead's initial top-line Phase IIa data showed good knockdown of s-antigen, durability, and safety. The firm expects shares to trade up on the news and notes doctors say increased doses and time could lead to higher cures of Hep B. Shares are Outperform rated.
07:36 EDTARWRArrowhead shares recommended after ARC-520 data at Deutsche Bank
Subscribe for More Information
06:35 EDTARWRArrowhead shares likely weak on lack of data, says Piper Jaffray
Piper Jaffray expects shares of Arrowhead to be under pressure following the company's Q3 results given the lack of data for ARC-520 for the treatment of hepatitis-B virus infection. Piper keeps an Overweight rating on the stock with a $24 price target.
August 12, 2014
19:02 EDTARWROn The Fly: After Hours Movers
Subscribe for More Information
16:16 EDTARWRArrowhead Research provides update on phase 2a study of ARC-520
Arrowhead Research completed its dosing of 1mg/kg and 2mg/kg dose cohorts. The company's initial blinded data suggest that the magnitude of HBsAg knockdown is similar to non-human primate studies, including the chronically infected chimpanzee reported on previously. ARC-520 continues to be well tolerated, with no dropouts or serious adverse events reported. The overall rate of AEs has been lower in the phase 2a than in the phase 1 normal volunteer study and safety labs continue to show no indication of end organ toxicity. The company received IRB and DSMB approvals to proceed and began enrolling an additional dose cohort at 3 mg/kg in the Phase 2a patient study.
16:13 EDTARWRArrowhead Research reports Q3 EPS (22c), consensus (22c)
Total operating expenses for the quarter were $12.7M, compared to $6.4M for the quarter ended June 30, 2013. The company’s cash and investments of cash were $188.5M at June 30.
August 11, 2014
05:53 EDTRHHBYCuris shares look attractive, says Piper Jaffray
Subscribe for More Information
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
August 8, 2014
11:33 EDTRHHBYRoche submits supplemental Biologics License application to FDA for Lucentis
Subscribe for More Information
10:03 EDTBMYBristol-Myers Hodgkin lymphoma treatment granted orphan drug status
Subscribe for More Information
06:51 EDTNVSJudge rules DOJ can pursue Novartis kickback suit, Reuters says
U.S. District Judge Colleen McMahon ruled that the U.S. Department of Justice is allowed to continue its False Claims Act lawsuit versus Novartis regarding allegations that the company used kickbacks to increase sales of medications covered by Medicare and Medicaid, according to Reuters, citing comments from McMahon. Reference Link
06:28 EDTARWRArrowhead Research volatility elevated
Subscribe for More Information
August 7, 2014
14:05 EDTRHHBYPTC Therapeutics reports publication of preclinical study results in SMA models
PTC Therapeutics (PTCT) announced that he journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy or SMA. Stuart Peltz, CEO of PTC Therapeutics, said, "Using the experience and expertise in RNA biology we have gained at PTC over the last 16 years, we used our alternative splicing technology to identify and subsequently optimize investigational compounds that target the SMN2 splicing to produce the SMN protein. Our unique partnership with Roche and the SMA Foundation has allowed this project to rapidly move into clinical development." Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche (RHHBY), said, "Although still preclinical, these results demonstrate how SMN2 splicing modifiers could correct the molecular deficit that causes SMA. This study represents an important step towards developing a potential therapeutic option for this devastating and currently untreatable condition. Early clinical trials are currently underway to determine the safety and tolerability of this approach."
11:02 EDTBMYBristol-Myers enters development pact with Leica Biosystem
Subscribe for More Information
08:38 EDTNVSEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information
August 6, 2014
10:43 EDTRHHBYRoche says Avastin gets EU approval for Ovarian cancer
Roche announced that the European Commission, EU, approved the use of Avastin in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy.
06:19 EDTRHHBYCFA Society of Minnesota to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use